Профиль компании · Healthcare

Mayinglong Pharmaceutical Group Co Ltd

600993 · Шанхай
Страна / Регион
China
Дата IPO
23 апреля 2004 г.
Сотрудники
2 544
Buffett Score
72/100
Сильный
Капитализация9,71 млрд CN¥
Выручка (TTM)3,93 млрд CN¥
EBITDA710,27 млн CN¥
Чистая маржа15,29 %
ROE14,16 %
P/E (TTM)16,2
Прогнозный P/E23,42
Прибыль на акцию1,39 CN¥
Дивидендная доходность3,15 %
Диапазон за 52 недели21,22 CN¥ – 30,18 CN¥

Данные EODHD, показаны в валюте отчётности; только для справки, не является инвестиционной рекомендацией.

Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells pharmaceutical packaging materials, cosmetics, and Chinese medicines; produces and sells health food; and offers class I and II medical devices, machinery, household goods, electronic products, daily necessities, hygiene products, and disinfection products, as well as road freight transportation services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; imports raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts and related technologies; and exports its products. Mayinglong Pharmaceutical Group Co., Ltd. was founded in 1582 and is headquartered in Wuhan, China.

История

СкороЭтот раздел заполняется — загляните позже.

Положение в отрасли

СкороЭтот раздел заполняется — загляните позже.

Аналитики по этой бумаге на вашем языке пока нет.